高原人群肺動脈高壓與血紅蛋白濃度的相關研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

廖霞 ¹ ,  LUO Fengming ²

1. ;
2. ;

Corresponding?author：

LUO Fengming, Email: luofengming@hotmail.com

Keywords：

DOI：

10.7507/1671-6205.202201028

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： LUO Fengming. 高原人群肺動脈高壓與血紅蛋白濃度的相關研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2022, 21(3): 225-228. doi: 10.7507/1671-6205.202201028 Copy

1.	Zubieta-Calleja G, Zubieta-DeUrioste N. The oxygen transport triad in high-altitude pulmonary edema: a perspective from the high Andes. Int J Environ Res Public Health, 2021, 18(14): 7619.
2.	Sydykov A, Mamazhakypov A, Maripov A, et al. Pulmonary hypertension in acute and chronic high altitude maladaptation disorders. Int J Environ Res Public Health, 2021, 18(4): 1692.
3.	邊巴瓊達, 徐鈺, 黃麗萍, 等. 高原地區藏族居民脈氧飽和度和血紅蛋白含量分析. 中國呼吸與危重監護雜志, 2018, 17(3): 271-274.
4.	Storz JF, Scott GR. Phenotypic plasticity, genetic assimilation, and genetic compensation in hypoxia adaptation of high-altitude vertebrates. Comp Biochem Physiol A Mol Integr Physiol, 2021, 253: 110865.
5.	Sydykov A, Maripov A, Kushubakova N, et al. an Exaggerated rise in pulmonary artery pressure in a high-altitude dweller during the cold season. Int J Environ Res Public Health, 2021, 18(8): 3984.
6.	吳天一. 高原紅細胞增多癥 82 例分析. 中華血液學雜志, 1979, 3(3): 27-30.
7.	Garrido E, Botella de Maglia J, Castillo O. Acute, subacute and chronic mountain sickness. Rev Clin Esp (Barc), 2021, 221(8): 481-490.
8.	吳天一. 高原醫學 40 年——中國高原醫學獲得的大成果. 高原醫學雜志, 2019, 29(1): 30-35.
9.	國際高原醫學會慢性高原病專家小組. 第六屆國際高原醫學和低氧生理學術大會頒布慢性高原病青海診斷標準. 青海醫學院學報, 2005, 26(1): 3-5.
10.	中華醫學會呼吸病學分會肺栓塞與肺血管病學組, 中國醫師協會呼吸醫師分會肺栓塞與肺血管病工作委員會, 全國肺栓塞與肺血管病防治協作組, 等. 中國肺動脈高壓診斷與治療指南(2021 版). 中華醫學雜志, 2021, 101(1): 11-51.
11.	Tang H, Vanderpool RR, Wang J, et al. Targeting L-arginine-nitric oxide-cGMP pathway in pulmonary arterial hypertension. Pulm Circ, 2017, 7(3): 569-571.
12.	Mizuno S, Ishizaki T, Toga H, et al. Endogenous Asymmetric dimethylarginine pathway in high altitude adapted yaks. Biomed Res Int, 2015, 2015: 196904.
13.	久太, 馮喜英, 關巍, 等. 急性高原肺水腫患者 ODC1 蛋白表達差異與肺動脈高壓的相關性研究. 臨床肺科雜志, 2017, 22(12): 2160-2163.
14.	崔建華, 張西洲, 何富文, 等. 不同海拔高度居住高原不同時間健康青年血漿內皮素和一氧化氮的測定. 西藏醫藥雜志, 1999, 20(4): 1-2,73.
15.	Lai YC, Potoka KC, Champion HC, et al. Pulmonary arterial hypertension: the clinical syndrome. Circ Res, 2014, 115(1): 115-130.
16.	劉鑫源, 陳興書, 羅勇軍. 波生坦防治高原肺動脈高壓相關疾病研究進展. 人民軍醫, 2020, 63(1): 79-83.
17.	Sharma K, Mishra A, Singh HN, et al. High-altitude pulmonary edema is aggravated by risk loci and associated transcription factors in HIF-prolyl hydroxylases. Hum Mol Genet, 2021, 30(18): 1734-1749.
18.	Qin S, Predescu D, Carman B, et al. Up-regulation of the long noncoding RNA x-inactive-specific transcript and the sex bias in pulmonary arterial hypertension. Am J Pathol, 2021, 191(6): 1135-1150.
19.	Lichtblau M, Saxer S, Furian M, et al. Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m. Eur Respir J, 2020, 56(2): 1902474.
20.	Soria R, Egger M, Scherrer U, et al. Pulmonary artery pressure and arterial oxygen saturation in people living at high or low altitude: systematic review and meta-analysis. J Appl Physiol (1985), 2016, 121(5): 1151-1159.
21.	Gou Q, Shi R, Zhang X, et al. The prevalence and risk factors of high-altitude pulmonary hypertension among native Tibetans in Sichuan province, China. High Alt Med Biol, 2020, 21(4): 327-335.
22.	Negi PC, Marwaha R, Asotra S, et al. Prevalence of high altitude pulmonary hypertension among the natives of Spiti Valley—a high altitude region in Himachal Pradesh, India. High Alt Med Biol, 2014, 15(4): 504-510.
23.	Maggiorini M, Léon-Velarde F. High-altitude pulmonary hypertension: a pathophysiological entity to different diseases. Eur Respir J, 2003, 22(6): 1019-1025.
24.	Naeije R. Altitude and the right heart. Rev Mal Respir, 2018, 35(4): 441-451.
25.	Peth? D, Hendrik Z, Nagy A, et al. Heme cytotoxicity is the consequence of endoplasmic reticulum stress in atherosclerotic plaque progression. Sci Rep, 2021, 11(1): 10435.
26.	Gutiérrez-Mu?oz C, Méndez-Barbero N, Svendsen P, et al. CD163 deficiency increases foam cell formation and plaque progression in atherosclerotic mice. FASEB J, 2020, 34(11): 14960-14976.
27.	James J, Srivastava A, Varghese MV, et al. Heme induces rapid endothelial barrier dysfunction via the MKK3/p38MAPK axis. Blood, 2020, 136(6): 749-754.
28.	Ashouri R, Fangman M, Burris A, et al. Critical role of hemopexin mediated cytoprotection in the pathophysiology of sickle cell disease. Int J Mol Sci, 2021, 22(12): 6408.
29.	Zhang P, Nguyen J, Abdulla F, et al. Soluble MD-2 and heme in sickle cell disease plasma promote pro-inflammatory signaling in endothelial cells. Front Immunol, 2021, 12: 632709.
30.	Buehler PW, D’Agnillo F, Schaer DJ. Hemoglobin based oxygen carriers: from mechanisms of toxicity and clearance to rational drug design. Trends Mol Med, 2010, 16: 447-457.
31.	Pan YK, Ern R, Morrison PR. Acclimation to prolonged hypoxia alters hemoglobin isoform expression and increases hemoglobin oxygen affinity and aerobic performance in a marine fish. Sci Rep, 2017, 7(1): 7834.
32.	Parikh J, Kapela A, Tsoukias NM. Can endothelial hemoglobin-α regulate nitric oxide vasodilatory signaling?. Am J Physiol Heart Circ Physiol, 2017, 312(4): H854-H866.
33.	Wan BN, Zhou SG, Wang M, et al. Progress on haptoglobin and metabolic diseases. World J Diabetes, 2021, 12(3): 206-214.
34.	Oh MK, Kim IS. Involvement of placental growth factor upregulated via TGF-β1-ALK1-Smad1/5 signaling in prohaptoglobin-induced angiogenesis. PLoS One, 2019, 14(4): e0216289.
35.	Yang Y, Gao C, Yang T, et al. Vascular characteristics and expression of hypoxia genes in Tibetan pigs' hearts. Vet Med Sci, 2022, 8(1): 177-186.
36.	Alvarez RA, Miller MP, Hahn SA, et al. Targeting pulmonary endothelial hemoglobin α improves nitric oxide signaling and reverses pulmonary artery endothelial dysfunction. Am J Respir Cell Mol Biol, 2017, 57(6): 733-744.
37.	Sánchez K, Ballaz SJ. Might a high hemoglobin mass be involved in non-cardiogenic pulmonary edema? The case of the chronic maladaptation to high-altitude in the Andes. Med Hypotheses, 2021, 146: 110418.
38.	何宗釗, 鄧莉, 馬四清, 等. 不同海拔漢族健康人大循環及微循環特征的對比. 中國應用生理學雜志, 2021, 37(4): 371-376.
39.	Rochon ER, Corti P, Gladwin MT. Hemoglobin α in pulmonary endothelium: ironing out nitric oxide signaling. Am J Respir Cell Mol Biol, 2017, 57(6): 639-641.
40.	Stembridge M, Hoiland RL, Williams AM, et al. The influence of hemoconcentration on hypoxic pulmonary vasoconstriction in acute, prolonged, and lifelong hypoxemia. Am J Physiol Heart Circ Physiol, 2021, 321(4): H738-H747.

1. Zubieta-Calleja G, Zubieta-DeUrioste N. The oxygen transport triad in high-altitude pulmonary edema: a perspective from the high Andes. Int J Environ Res Public Health, 2021, 18(14): 7619.
2. Sydykov A, Mamazhakypov A, Maripov A, et al. Pulmonary hypertension in acute and chronic high altitude maladaptation disorders. Int J Environ Res Public Health, 2021, 18(4): 1692.
3. 邊巴瓊達, 徐鈺, 黃麗萍, 等. 高原地區藏族居民脈氧飽和度和血紅蛋白含量分析. 中國呼吸與危重監護雜志, 2018, 17(3): 271-274.
4. Storz JF, Scott GR. Phenotypic plasticity, genetic assimilation, and genetic compensation in hypoxia adaptation of high-altitude vertebrates. Comp Biochem Physiol A Mol Integr Physiol, 2021, 253: 110865.
5. Sydykov A, Maripov A, Kushubakova N, et al. an Exaggerated rise in pulmonary artery pressure in a high-altitude dweller during the cold season. Int J Environ Res Public Health, 2021, 18(8): 3984.
6. 吳天一. 高原紅細胞增多癥 82 例分析. 中華血液學雜志, 1979, 3(3): 27-30.
7. Garrido E, Botella de Maglia J, Castillo O. Acute, subacute and chronic mountain sickness. Rev Clin Esp (Barc), 2021, 221(8): 481-490.
8. 吳天一. 高原醫學 40 年——中國高原醫學獲得的大成果. 高原醫學雜志, 2019, 29(1): 30-35.
9. 國際高原醫學會慢性高原病專家小組. 第六屆國際高原醫學和低氧生理學術大會頒布慢性高原病青海診斷標準. 青海醫學院學報, 2005, 26(1): 3-5.
10. 中華醫學會呼吸病學分會肺栓塞與肺血管病學組, 中國醫師協會呼吸醫師分會肺栓塞與肺血管病工作委員會, 全國肺栓塞與肺血管病防治協作組, 等. 中國肺動脈高壓診斷與治療指南(2021 版). 中華醫學雜志, 2021, 101(1): 11-51.
11. Tang H, Vanderpool RR, Wang J, et al. Targeting L-arginine-nitric oxide-cGMP pathway in pulmonary arterial hypertension. Pulm Circ, 2017, 7(3): 569-571.
12. Mizuno S, Ishizaki T, Toga H, et al. Endogenous Asymmetric dimethylarginine pathway in high altitude adapted yaks. Biomed Res Int, 2015, 2015: 196904.
13. 久太, 馮喜英, 關巍, 等. 急性高原肺水腫患者 ODC1 蛋白表達差異與肺動脈高壓的相關性研究. 臨床肺科雜志, 2017, 22(12): 2160-2163.
14. 崔建華, 張西洲, 何富文, 等. 不同海拔高度居住高原不同時間健康青年血漿內皮素和一氧化氮的測定. 西藏醫藥雜志, 1999, 20(4): 1-2,73.
15. Lai YC, Potoka KC, Champion HC, et al. Pulmonary arterial hypertension: the clinical syndrome. Circ Res, 2014, 115(1): 115-130.
16. 劉鑫源, 陳興書, 羅勇軍. 波生坦防治高原肺動脈高壓相關疾病研究進展. 人民軍醫, 2020, 63(1): 79-83.
17. Sharma K, Mishra A, Singh HN, et al. High-altitude pulmonary edema is aggravated by risk loci and associated transcription factors in HIF-prolyl hydroxylases. Hum Mol Genet, 2021, 30(18): 1734-1749.
18. Qin S, Predescu D, Carman B, et al. Up-regulation of the long noncoding RNA x-inactive-specific transcript and the sex bias in pulmonary arterial hypertension. Am J Pathol, 2021, 191(6): 1135-1150.
19. Lichtblau M, Saxer S, Furian M, et al. Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m. Eur Respir J, 2020, 56(2): 1902474.
20. Soria R, Egger M, Scherrer U, et al. Pulmonary artery pressure and arterial oxygen saturation in people living at high or low altitude: systematic review and meta-analysis. J Appl Physiol (1985), 2016, 121(5): 1151-1159.
21. Gou Q, Shi R, Zhang X, et al. The prevalence and risk factors of high-altitude pulmonary hypertension among native Tibetans in Sichuan province, China. High Alt Med Biol, 2020, 21(4): 327-335.
22. Negi PC, Marwaha R, Asotra S, et al. Prevalence of high altitude pulmonary hypertension among the natives of Spiti Valley—a high altitude region in Himachal Pradesh, India. High Alt Med Biol, 2014, 15(4): 504-510.
23. Maggiorini M, Léon-Velarde F. High-altitude pulmonary hypertension: a pathophysiological entity to different diseases. Eur Respir J, 2003, 22(6): 1019-1025.
24. Naeije R. Altitude and the right heart. Rev Mal Respir, 2018, 35(4): 441-451.
25. Peth? D, Hendrik Z, Nagy A, et al. Heme cytotoxicity is the consequence of endoplasmic reticulum stress in atherosclerotic plaque progression. Sci Rep, 2021, 11(1): 10435.
26. Gutiérrez-Mu?oz C, Méndez-Barbero N, Svendsen P, et al. CD163 deficiency increases foam cell formation and plaque progression in atherosclerotic mice. FASEB J, 2020, 34(11): 14960-14976.
27. James J, Srivastava A, Varghese MV, et al. Heme induces rapid endothelial barrier dysfunction via the MKK3/p38MAPK axis. Blood, 2020, 136(6): 749-754.
28. Ashouri R, Fangman M, Burris A, et al. Critical role of hemopexin mediated cytoprotection in the pathophysiology of sickle cell disease. Int J Mol Sci, 2021, 22(12): 6408.
29. Zhang P, Nguyen J, Abdulla F, et al. Soluble MD-2 and heme in sickle cell disease plasma promote pro-inflammatory signaling in endothelial cells. Front Immunol, 2021, 12: 632709.
30. Buehler PW, D’Agnillo F, Schaer DJ. Hemoglobin based oxygen carriers: from mechanisms of toxicity and clearance to rational drug design. Trends Mol Med, 2010, 16: 447-457.
31. Pan YK, Ern R, Morrison PR. Acclimation to prolonged hypoxia alters hemoglobin isoform expression and increases hemoglobin oxygen affinity and aerobic performance in a marine fish. Sci Rep, 2017, 7(1): 7834.
32. Parikh J, Kapela A, Tsoukias NM. Can endothelial hemoglobin-α regulate nitric oxide vasodilatory signaling?. Am J Physiol Heart Circ Physiol, 2017, 312(4): H854-H866.
33. Wan BN, Zhou SG, Wang M, et al. Progress on haptoglobin and metabolic diseases. World J Diabetes, 2021, 12(3): 206-214.
34. Oh MK, Kim IS. Involvement of placental growth factor upregulated via TGF-β1-ALK1-Smad1/5 signaling in prohaptoglobin-induced angiogenesis. PLoS One, 2019, 14(4): e0216289.
35. Yang Y, Gao C, Yang T, et al. Vascular characteristics and expression of hypoxia genes in Tibetan pigs' hearts. Vet Med Sci, 2022, 8(1): 177-186.
36. Alvarez RA, Miller MP, Hahn SA, et al. Targeting pulmonary endothelial hemoglobin α improves nitric oxide signaling and reverses pulmonary artery endothelial dysfunction. Am J Respir Cell Mol Biol, 2017, 57(6): 733-744.
37. Sánchez K, Ballaz SJ. Might a high hemoglobin mass be involved in non-cardiogenic pulmonary edema? The case of the chronic maladaptation to high-altitude in the Andes. Med Hypotheses, 2021, 146: 110418.
38. 何宗釗, 鄧莉, 馬四清, 等. 不同海拔漢族健康人大循環及微循環特征的對比. 中國應用生理學雜志, 2021, 37(4): 371-376.
39. Rochon ER, Corti P, Gladwin MT. Hemoglobin α in pulmonary endothelium: ironing out nitric oxide signaling. Am J Respir Cell Mol Biol, 2017, 57(6): 639-641.
40. Stembridge M, Hoiland RL, Williams AM, et al. The influence of hemoconcentration on hypoxic pulmonary vasoconstriction in acute, prolonged, and lifelong hypoxemia. Am J Physiol Heart Circ Physiol, 2021, 321(4): H738-H747.

Previous Article
經氣管插管機械通氣對呼吸道菌群影響的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

高原人群肺動脈高壓與血紅蛋白濃度的相關研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content